Abraxis expands in Phoenix

Los Angeles-based Abraxis BioScience is expanding its Phoenix manufacturing facility, creating 200 new jobs in the area. "When all is said and done, this will be a $100 million investment," said Dr. Patrick Soon-Shiong, chairman of Abraxis. The company drug, Abraxane, has been approved in the U.S. and 38 other countries for breast cancer; it's currently in Phase III clinical trials for pancreatic, melanoma and lung cancer. Report

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.